Cory Watson Crowder & DeGaris, P.C.

On February 8, 2006, the FDA issued a public health advisory on Bayer AG’s Trasylol®, after newly published research links the drug with increased risk of kidney failure, heart attacks and strokes. Trasylol, generically known as aprotinin, is frequently used during open heart surgery to control bleeding. The medication is administered intravenously during surgery and patients are rarely made aware that they have received the medication. In most instances we will have to obtain medical records to confirm use of Trasylol.

In January of 2006, a study published in the New England Journal of Medicine (NEJM) revealed that Trasylol, doubled the risk of kidney failure in patients, also increased the risk of heart attack by 48%, heart failure by 109%, and stroke by 181%. Theses injuries generally occur during the hospital stay or shortly thereafter.

We welcome referral for clients who underwent heart bypass surgery, were administered Trasylol and suffered kidney failure, heart attack, or stroke.

We have extensive medical and scientific material available and an intake and client screening packet available for anyone interested.

An additional warning issued by the Associated Press on February 17, 2006 stated that women who use the Ortho Evra birth-control patch face twice the risk of developing blood clots than those who take the pill.

Release of interim results from Johnson & Johnson comes four months after the Food and Drug Administration warned women that the increased levels of hormones released by the patch put them at higher risk of blood clots and other serious side effects. Ortho said it shared the results of the latest studies with the FDA. Additions to the patch label made in November warned women that they would be exposed to about 60 percent more estrogen than those who use birth-control pills.

An investigation by the AP last year found that the patch users die and suffer blood clots at a rate three times higher than women taking the pill. About a dozen women died in 2004 from blood clots believed linked to use of the patch. Dozens more suffered strokes and other clot-linked problems.

CWCD is actively involved in these cases. Currently we have cases filed against Johnson & Johnson and Ortho McNeil, the makers of the patch, in Alabama and Kentucky. Nationally, there has been a petition filed requesting the formation of an MDL. We are interested in cases of women who have suffered pulmonary embolisms, DVTs, or other clotting events while on the Ortho Evra patch.

We have extensive medical and scientific material available and an intake and client screening packet for anyone interested. Ernie Cory is heading up this litigation. Please direct any questions that you have to them.

Refer a Colleague
If you have a colleague who would benefit from receiving the eBulletin, contact Sonya Cory at scory@cwcd.com .

Update Your Contact Information
You may change your email address, update your contact information or unsubscribe from the eBulletin at any time by contacting Sonya Cory at scory@cwcd.com.